Menu
Recruiting NCT05682417

Impact of Body Schema Distortion on Remission and Weight Regain in Anorexia Nervosa

No phase Interventional Anorexia Nervosa

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Body Map Assessment Tool: MOVE Tool, PAQ questionnaire, F-DFlex questionnaire, BSQ questionnaire.
Who it may be relevant to
Registry conditions: Anorexia Nervosa. Basic parameters: from 15 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Anorexia nervosa is a predominantly female eating disorder that most often appears in adolescence. The latter leads to strict and voluntary food deprivation for several months or even years. The lifetime prevalence of anorexia is 1.4% in women and 0.2% in men. Ultimately, only half of people treated for anorexia nervosa in adolescence recover, 30% simply improve, 21% suffer from chronic disorders and 5 to 6% die. At the same time, between a quarter and half of patients abandon their current treatment, including during hospitalization. Relapses occur during the evolution of anorexia nervosa. Even more worrying, mortality is highest the year following the patient's discharge from hospital. This appears to be due to somatic complications in more than half of cases (most often cardiac arrest), to suicide in 27% of cases. Researchers are still trying to clarify the mechanisms involved in the emergence and persistence of this disorder. The objective is to obtain more verified and faster cures. However, the obstacles to successful treatment are mainly due to the denial of disorders and thinness. From a neurocognitive perspective, the representation one has of one's body is underpinned by two types of representations, i.e. body image and body schema. It has long been shown that body image is altered in anorexia nervosa. More recently, authors have shown that the distortion of the body representation was however more extensive and also affected the body schema. Patients find themselves too fat despite obvious thinness and move through space as if this were really the case. Worryingly, these distortions in bodyschema seem to persist after therapeutic management. Despite the potential role of body-scheme distortions in maintaining the disorder, as well as the risk of relapse, the difficulties in assessing body-scheme are significant. Indeed, recovery in these pathologies is often determined according to the Body Mass Index, self-declaration and questionnaires evaluating body image, again limiting the verification of the resorption of distortions in the body schema. Investigators have therefore developed the systematic, ergonomic and simplified evaluation of the body schema in patients suffering from anorexia nervosa at the time of diagnosis in an expert center, but also during follow-up evaluations thanks to the use of an evaluation platform of the body schema, i.e. the body in brain platform, developed by the LIP/PC2S laboratory and the SATT Linksium which allows the evaluation of the body schema.

Interventions

  • Device Body Map Assessment Tool: MOVE Tool
    In VR, a spherical object approaches with linear trajectory the body of patients, it can be sent to 4 parts of the body (mid-arm/waist/hip/mid-thigh) both left and right side. Several conditions are presented, either the trajectory leads the object to touch the body, or it passes at ≠ distances from it. Patient is instructed to move only if he thinks the object will touch his body. Procedure begins with a measurement taken on 3 body locations via the Move tool (shoulders/hips/thighs) to create
  • Other PAQ questionnaire
    This questionnaire has been translated and validated (French version, Luminet et al., 2021). This is a self-reported measure of alexithymia in 24 items. It is designed to measure all the components of alexithymia for both negative and positive emotions. Five subscale scores and six composite scores can be obtained from the questionnaire, with high scores indicating higher levels of alexithymia.
  • Other F-DFlex questionnaire
    This questionnaire (Detail and Flexibility Questionnaire, French version of Maria et al, 2020) assesses cognitive rigidity. This questionnaire assesses two frequently impaired cognitive dimensions in people with anorexia nervosa, central coherence and cognitive flexibility in daily functioning using 20 self-completed items.
  • Other BSQ questionnaire
    The Body Shape Questionnaire (BSQ, translated and validated in French by Rousseau et al., 2005) is a one-dimensional Anglo-Saxon self-questionnaire of 34 items that assesses concerns about body shape over the past four weeks. Responses are scored on a 6-point Likert scale. A score of 1 ("never") means the problem is not present, up to a score of 6 ("always") which means the problem is always present. The higher the score, the more the concern/dissatisfaction with one's body tends to be pathologi
  • Other Silhouette testing
    Body overestimation is assessed by the computerized silhouette test (adapted from Gardner \& Brown, 2010, Van der Linder et al., 2017). Twenty-seven Body Mass Index silhouettes ranging from 11 to 40 are presented to participants in random order. For each silhouette presented, the participant answers whether or not the silhouette presented corresponds to her current silhouette. A body underestimation index is calculated as follows: Estimated figure average BMI - actual BMI.
  • Other Eating Disorder Inventory - 2
    Allows self-assessment of symptoms of eating disorders. It is composed of 91 questions grouped into 11 subscales that assess specific cognitive and behavioral dimensions: desire for thinness, bulimia, body dissatisfaction, feeling of inefficiency, perfectionism, interpersonal distrust, interoceptive sensitivity, fears relating to maturity, asceticism. , impulsiveness and social insecurity. For each item, participants can answer "always", "usually", "often", "sometimes", "rarely" or "never". The
  • Other EDEQ questionnaire
    Or "Eating Disorders Examination - Questionnaire" (Fairburn \& Beglin, 2008). This questionnaire assesses eating behaviors and concerns about weight and body shape, using 28 items focusing on these aspects over the past 28 days.
  • Other STAI questionnaire
    The Spielberger Anxiety Scale (STAI) State and Trait. This questionnaire includes two distinct scales: one evaluating the current state of anxiety (STAI form Y-A: feelings of apprehension, tension, nervousness and worry that the subject feels at a precise precise moment) and the second evaluating the anxious personality trait (STAI form Y-B: feelings of apprehension, tension, nervousness, and worry that the subject usually feels). The Y version was developed in order to eliminate the items havin
  • Other BECK questionnaire
    Beck Depression Inventory (Beck, 1987). The inventory is composed of items related to depressive symptoms as well as physical symptoms. This is a questionnaire that gives a quantitative estimate of the intensity of depression. Investigators will use the abbreviated version consisting of 13 items, each item comprising 4 sentences corresponding to 4 degrees of increasing intensity of a symptom on a scale of 0 to 3. The total score corresponds to the sum of the different items and makes it possible

Primary outcome measures

  • Overestimation of the body schema [Time frame: Baseline (T0); 6 months after baseline (T+6); 12 months after baseline (T+12)]
Secondary outcome measures (9)
  • Weight/height ratio, expressed by body mass index (BMI) [Time frame: Baseline T0; 6 months; 12 months]
  • Body overstatement [Time frame: Baseline T0; 6 months; 12 months]
  • Alexithymia score [Time frame: Baseline T0; 6 months; 12 months]
  • Cognitive rigidity score [Time frame: Baseline T0; 6 months; 12 months]
  • Body dissatisfaction score [Time frame: Baseline T0; 6 months; 12 months]
  • Eating behavior assessed by the EDI-2 questionnaire [Time frame: Baseline T0; 6 months; 12 months]
  • Eating behavior assessed by the EDE-Q questionnaire [Time frame: Baseline T0; 6 months; 12 months]
  • Level of anxiety [Time frame: Baseline T0; 6 months; 12 months]
  • Level of Depression [Time frame: Baseline T0; 6 months; 12 months]

Eligibility criteria

Inclusion criteria

  • Patient over 15 years old
  • Women
  • Patient with a BMI <18.5
  • Patient suffering from anorexia nervosa (DSM V, 2013)
  • Patient agreeing to participate in the study with signed informed consent (Or whose parents/holder of parental authority have signed the informed consent)
  • Patient affiliated to a Social Security plan or beneficiary of such a plan

Exclusion criteria

  • Adult patients protected by a legal protection measure (guardianship, curatorship, etc.)
  • Patients participating in another research that may interfere with this research
  • Patients with acute and co-occurring psychiatric comorbidities (suicidal crisis, delusions)
  • Patients not fluent in French
  • Pregnant, parturient or breastfeeding women (on questioning of the patient)
  • Persons deprived of their liberty by a judicial or administrative decision
  • Persons admitted to a health or social establishment for purposes other than research
  • Patients with any current pathology or history of psychotic disorders, migraine, epilepsy, balance disorders, vertigo, visual disorders, proprioceptive disorders and/or neuromuscular disorders.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

France · 1 center
  • Referral Center for Eating Disorders. Neurological Hospital-GH East / Hôpital Neurologique — Bron

Identifiers

NCT: NCT05682417 · 69HCL21_1364

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗